THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN ...

SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, ...

Third Harmonic Bio, Inc. ( (THRD) ) has released its Q3 earnings. Here is a breakdown of the information Third Harmonic Bio, Inc. presented to ...

SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal ...

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Third Harmonic Bio, Inc. (THRD – Research Report). The ...

A live audio webcast of each fireside chat will be available within the Investors & Media section of the Third Harmonic Bio website. Archived replays will be accessible for 90 days following the ...

Third Harmonic Bio, Inc. (NASDSAQ: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, ...

Short interest in Third Harmonic Bio Inc (NASDAQ:THRD) increased during the last reporting period, rising from 2.21M to 2.78M. This put 14.98% of the company's publicly available shares short.

Conner Edward R., the Chief Medical Officer of Third Harmonic (NASDAQ:HLIT) Bio, Inc. (NASDAQ:THRD), recently executed a series of stock transactions, according to a recent filing. On October 28 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...